Dr. Daphna Yael Spiegel, MD

Dr. Spiegel practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Spiegel's NPI, 1548607021, was assigned on May 24, 2013. Dr. Spiegel holds Massachusetts license 274585.

Dr. Spiegel's primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Spiegel's primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Spiegel is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Spiegel to 1 more hospital and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spiegel practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Spiegel's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Spiegel's licenses on file in 2 states: Massachusetts and North Carolina.

CMS data shows 903 Medicare services from Dr. Spiegel across 17 procedure codes in 2024, for 110 Medicare patients. Medicare paid $65,784 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 110 Medicare patients who saw Dr. Spiegel in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have cancer, and 69% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Spiegel's median patient age at 62, with 89% women.

In 2024, Dr. Spiegel wrote 49 Medicare Part D claims for 22 patients. 100% of them were for generic drugs. CMS names the drug for 24 of them, across 1 drug with 11 or more claims each, at $376 in total drug cost. In 2023, CMS named 47 claims across 2 drugs.

Dr. Spiegel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spiegel as offering telehealth.

Dmand AI links 19 papers to Dr. Spiegel, published from 2011 to 2025. 2018 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Radiation Oncology and Adenocarcinoma. Dr. Spiegel has published most often in Int J Radiat Oncol Biol Phys. Dr. Spiegel's most frequent co-authors are Julian C. Hong, MD, MS, Joseph Kamel Salama, MD and Manisha Palta, MD.

Dmand AI links Dr. Spiegel to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 2 general payments to Dr. Spiegel from 2 drug and device companies from 2018 to 2024. Food and beverage make up the largest share, 100% of the total. Bioprotect Medical, Inc. paid the most, $31.